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To the Editor: A recent article has reported the burden of uremic
pruritus (UP) in patients with end-stage renal disease.1 We would
like to highlight the characteristics of UP in the hemodialysis
(HD) patients.
A total of 102 efficiently dialyzed patients (63 men and 39
women) have been studied. The prevalence of UP was
measured quantitatively with the use of pruritus score and
visual analog scale obtained from the processing of a
specialized questionnaire. Patients were on dialysis and on
a steady clinical state for more than 3 months and during the
study period they did not present any active primary skin
disorder or any systemic disorder with skin lesions. High-flux
and super-flux filters were used in the dialysis procedure and
a standard dose of the same low molecular weight heparin
was administered in each dialysis session.
Of the 102 patients (48.5%), 50 suffered from UP. In 29/50
(58% of those with UP and 28.7% of the total) presented
with UP in 1–40% of their body surface area. In 7/50 (14% of
those with UP and 6.8% of the total) presented UP in 41–70%
of the body surface area) and 14/50 of the patients (28% of
those with UP and 13% of the total) presented with UP in
71–100% of their body surface area. In 18/50 of the patients
with UP (36%) were receiving a special treatment for UP
consisting of antihistamines, sedatives and emollients with
relative alleviation. Among the 50 patients with UP 27 (54%)
believe that UP is seriously affecting their quality of life.
In 17/50 (34%) did not notice any change in UP intensity
during dialysis. In 24/50 (48%) UP was less intense and in 9/50
(18%) UP was worsening during dialysis. In 27/50 (54%) UP
intensity remained unchanged, in 4/50 (8%) UP was more
intense during the day of dialysis, in 11/50 (22%) UP was
exacerbated during the next day post-dialysis and in 9/50
(18%) UP was intensified following a period of 3 days without
dialysis.
In conclusion, UP in efficiently dialyzed patients remains a
significant problem that can seriously influence their quality
of life. Further investigations will be needed in order to
uncover the underlying mechanism(s).
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Kosmadakis et al. highlight the importance of pruritus in a
hemodialysis cohort.1 It is not possible for us to critically
comment on the data that Kosmadakis et al. provide as
information on the assembly of the cohort and demographic
and clinical characteristics of the population are not provided
in detail. However, their estimate of the prevalence of pruritus
in the dialysis population is similar in magnitude to other
estimates published previously and discussed in our recent
article.2 Kosmadakis et al. present data that 34% of patients in
their cohort did not report change in the intensity of uremic
pruritus during dialysis, whereas 48% reported uremic
pruritus to be less intense and 18% reported worsening
during dialysis. Overall, uremic pruritus intensity remained
unchanged in 54% of the subjects in their cohort despite 36%
of their patients receiving treatment with antihistamines,
sedatives, and emollients. Although several studies have tested
the efficacy of various therapies, including, ultraviolet B
phototherapy,3,4 high efficiency dialysis,5 gabapentin,6,7 capsai-
cin,8 and naltrexone9,10 for uremic pruritus, these studies
have methodologic limitations. The letter by Kosmadakis et al.
underscores the inadequacy of current therapeutic strategies
for uremic pruritus. We believe that properly designed
randomized trials to evaluate the benefit of improved
metabolic control and/or pharmacologic interventions are
warranted.
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Noninferiority of biocompatible
solutions in peritoneal dialysis
cannot be maintained
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To the Editor: We read with interest the results of the clinical
trial comparing biocompatible with standard solutions in
peritoneal dialysis.1 We believe that the authors’ claim of
noninferiority of biocompatible solutions compared to
standard solutions is not supported by their data. If the
difference in the mean of urea and creatinine clearance,
DnCrCl, between the two groups was 6.5 l per week and its
standard deviation was 6 l per week then its 95% confidence
interval was 18.42 to 5.42 l per week and the corresponding
figures in ml/min units were 1.87 ml/min (1.83 to
0.54 ml/min).2 As a result, a noninferiority hypothesis set
on the assumption that the difference is less than 1 ml/min
cannot be maintained as the lower limit of the 95%
confidence interval, 1.83 ml/min, is far lower than
1 ml/min.
We do not understand how the probabilities of actual
differences in DnCrCl or DUvol being greater than particular
figures were calculated, especially DnCrCl, highly incon-
sistent with its confidence interval. Standard, frequentist,
statistics can only calculate the probability that a test statistic
would be as extreme as or more extreme than observed if the
null hypotheses were true, the P-value. Alternatively, Bayesian
statistics can provide those probabilities,3 but no mention
was made of it in the article.
Further studies with larger sample sizes are needed also to
assess whether biocompatible solutions are indeed noninfer-
ior to standard solutions.
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I thank Dr Garcia-Lopez for asking me to clarify the
statistics I used in my article.
Existing publications (including his own1) suggest that
biocompatible peritoneal dialysis solutions would be super-
ior than standard. With this in mind, we wished to
determine if patients using biocompatible peritoneal dialysis
solutions would have a smaller decrement in nCrCl. We
decided to use a predefined cutoff that we felt was clinically
relevant, of 1 ml/min; that is inferiority of standard solutions
would be proven if DnCrClbiocom–DnCrClstand4þ 1 ml/min.
Dr Garcia Lopez has correctly calculated that the 95%
confidence interval for DnCrClbiocom–DnCrClstand was 1.83
to þ 0.54 ml/min. As þ 1 ml/min falls outside this range, we
could not demonstrate that standard solutions were inferior
(that is, we demonstrated noninferiority).
The difference between the expected DnCrCl (þ 1 ml/min)
and the observed DnCrCl (0.64 ml/min) was 1.64 ml/min.
The standard error was 0.6, therefore the observed DnCrCl
was42.7 s.e. outside the expected DnCrCl. The probability of
randomly selecting a group of normally distributed patients
who lie42.7 s.e. from the expected mean is B0.003.
We claimed that standard solutions are not inferior to
biocompatible (with regard to preserving residual renal
function in unselected incident peritoneal dialysis
patients). I therefore strongly refute any suggestions that
our claims are not supported by data.
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To the Editor: Davenport et al.1 were able to write an article
on hypertension control in dialysis patients of several
thousand words in length without mentioning the word salt.
This is curious given the wide publicity that an article by
Cook et al.2 on the highly significant benefit obtained with
5–6 g salt intake per day in reducing cardiovascular morbidity
and mortality in a ‘prehypertensive healthy population’. The
study, over a 10-year period, was randomized and controlled,
and involved several thousand individuals.2 This latter
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